Jcog1113
WebDisclaimer: These codes may not be the most recent version.Georgia may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Web24 giu 2024 · Based on these studies, a randomized phase III trial (JCOG1113 study) is ongoing to confirm the non-inferiority of GS relative to GC, which is the current standard treatment for chemo-naive patients with unresectable or recurrent BTC . Therefore, our group performed a phase I trial of GCS, triplet regimen . As this ...
Jcog1113
Did you know?
Web胆道癌 FUGA‐BT（JCOG1113） Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Morizane C, et al. … Web19 gen 2024 · Between May 8, 2013 and March 4, 2016, a total of 354 patients were enrolled to JCOG1113; 175 were assigned to the GC arm and 179 to the GS arm. For this subgroup analysis to investigate the influence of age, all registered patients of JCOG1113 were stratified by age; < 75 (non-elderly group) and ≥ 75 years (elderly group).
Web18 giu 2024 · JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). WebJCOG1113 (UMIN000010667) showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in terms of overall survival (OS) in patients (pts) with advanced BTCs. We aimed to compare clinical features among the primary sites of BTCs using JCOG1113 data. Methods: Among the 354 pts enrolled in JCOG1113, 352 pts were …
WebThe JCOG1113 study suggested that gemcitabine plus S-1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared to GC treatments. This study evaluates the efficacy and safety of a modified GS regimen. Web19 gen 2024 · 419. Background: JCOG1113 (UMIN000001685) is a randomized phase III trial in patients (pts) with advanced biliary tract cancers (BTCs) that shows the non-inferiority of gemcitabine plus S-1 (GS) to gemcitabine plus cisplatin (GC) regarding overall survival (OS). Previous reports suggest that a history of major hepatectomy (MH) may affect …
Web24 nov 2024 · A phase II study, JCOG0805 showed that gemcitabine plus S-1 was more promising than S-1 alone in ABTC, and a recently reported phase III JCOG1113 showed gemcitabine plus S-1 (GS) is non-inferiority to gemcitabine plus cisplatin (GC) in …
WebView detailed information about property 1613 County Road 5411, Oark, AR 72852 including listing details, property photos, school and neighborhood data, and much more. free weight exercises for shouldersWebJCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). free weight exercises for seniors pdfWeb9 apr 2024 · In the JCOG1113 study, 53% of patients in the GC group were treated with S-1 in second-line therapy, and the median OS of the patients receiving GC was 13.4 months . It should be noted that the results were limited to cases that could be treated with S-1 after becoming refractory to GC, although the OS of sequential therapy in both JCOG1113 … fashionista fosterWebRandomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT) Date of disclosure of the study information: 2013/05/08: Last modified on: 2024/01/05 13:46:57 fashionista for infantWeb1 giu 2024 · 4014 Background: Gemcitabine (GEM) plus cisplatin (GC) is the standard of care for advanced biliary tract cancer (BTC). However, GC is considered to be toxic because of nausea, vomiting, and appetite loss, and inconvenient due to requiring hydration before and after administration. GEM plus S-1 (GS) was reported to be promising with … fashionista for menWeb30 set 2024 · In 2024, the JCOG1113 study indicated that GEM plus S-1 (GEM/S-1) was not inferior in treating advanced biliary tract carcinoma, and it had an acceptable toxicity profile compared to GEM/CDDP in a ... fashionista foundationWebA phase II study, JCOG0805 showed that gemcitabine plus S-1 was more promising than S-1 alone in ABTC, and a recently phase III JCOG1113 (FUGA-BT) showed gemcitabine plus S-1 (GS) is non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) benefit. fashionista for male party decorations